Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canopy Growth Corp (CGC) vs Zoetis Inc (ZTS) Price & Performance

Canopy Growth CorpTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Canopy Growth Corp vs Zoetis Inc — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while Zoetis Inc trades at $74.67 (market cap $31.05B). The key difference: Zoetis Inc is far larger — about 77.9× Canopy Growth Corp's market cap, and Zoetis Inc pays a 2.86% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.

CGCZTS
Market Cap
$398.46M$31.05B
Sector
HealthHealth
52-Week High
$1.92$156.76
52-Week Low
$0.86$71.91
Enterprise Value
$337.90M$38.35B
Dividend Yield
2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canopy Growth Corp

Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.

The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.

Zoetis Inc

Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.

Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canopy Growth Corp

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Read more on CGC

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS